Explore another way you may receive treatment.

Potential OPDIVO® (nivolumab) user sitting in a field and drinking coffee with her partner.
Potential OPDIVO® (nivolumab) user sitting in a field and drinking coffee with her partner.

Clinical trial results for
advanced bladder or
urinary tract cancer

For certain previously untreated adults with
bladder cancer or urinary tract cancer
(urothelial carcinoma) that has spread or
cannot be removed by surgery

Actor portrayals.

An FDA-approved combination of immunotherapy and chemotherapy that helped people live longer compared to chemotherapy alone

About the clinical trial

In a clinical trial of 608 people with previously untreated advanced bladder or urinary tract cancer (urothelial carcinoma), 304 people were given OPDIVO + chemotherapy and 304 people were given chemotherapy alone. The chemotherapy medicines used for both groups in this clinical trial were cisplatin and gemcitabine.

People given OPDIVO + chemotherapy lived longer compared to
chemotherapy alone

At 22 months, half the people given OPDIVO® and chemotherapy were alive.
OPDIVO + chemotherapy

Half the people were alive

At 19 months, half the people given chemotherapy alone were alive.
Chemotherapy alone

Half the people were alive

People given OPDIVO + chemotherapy had a 22% lower risk of dying than those given chemotherapy alone.

People given OPDIVO + chemotherapy had a 38% lower risk of their cancer spreading, growing, or getting worse compared to those given chemotherapy alone.

OPDIVO + chemotherapy will not work for everyone. Individual results may vary.

OPDIVO Qvantig may be a faster* way to receive treatment.

It is not known if OPDIVO Qvantig is safe and effective in children. OPDIVO Qvantig cannot be used in combination with ipilimumab.
*A 3-5 minute injection time of OPDIVO Qvantig compared to a 30-minute infusion time of OPDIVO. This does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary.

Timer icon indicating the injection of OPDIVO® QVANTIG™ takes 3-5 minutes.
Hands exploring how OPDIVO® (nivolumab) works and learning how this treatment may help fight cancer.

How treatment works

See how this treatment may help your body fight cancer

OPDIVO® (nivolumab) side effects.

Side effects

View side effects of treatment and learn how to manage them

See treatment plans and what to expect from an OPDIVO® IV infusion or OPDIVO® QVANTIG™ subcutaneous injection.

Getting treatment

See treatment plans and what to expect from an intravenous (IV) infusion or under-the-skin injection (subcutaneous injection)

For previously untreated adults with urinary tract cancer (urothelial carcinoma) that has spread or cannot be removed by surgery

As an intravenous infusion

OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy medicines cisplatin and gemcitabine, as a first line treatment when your urinary tract cancer has spread (metastatic) or cannot be removed by surgery.

It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.

It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.

As a subcutaneous injection

OPDIVO Qvantig™ (nivolumab + hyaluronidase-nvhy) is a prescription medicine used in combination with chemotherapy medicines cisplatin and gemcitabine, as a first line treatment for adults whose urinary tract cancer has spread (metastatic) or cannot be removed by surgery.

It is not known if OPDIVO Qvantig is safe and effective in children.



466-US-2500010   03/25